Skip to main content

Table 3 Risk of bias in randomized controlled trials

From: Systematic evaluation of the methodology of randomized controlled trials of anticoagulation in patients with cancer

  Overall, n (%) N=67
Sequence generation  
Adequate 57 (85)
Not clear 10 (15)
Inadequate 0 (0)
Allocation concealment  
Adequate 41 (61)
Inadequate 3 (5)
Not clear 23 (34)
Participants blinded  
Definitely yes 5 (8)
Probably yes 21 (31)
Probably no 13 (19)
Definitely no 28 (42)
Caregiver blinded  
Definitely yes 5 (8)
Probably yes 22 (33)
Probably no 13 (19)
Definitely no 27 (40)
Data collector blinded  
Definitely yes 3 (5)
Probably yes 26 (39)
Probably no 13 (19)
Definitely no 25 (37)
Outcome assessor blinded  
Definitely yes 34 (51)
Probably yes 16 (24)
Probably no 7 (10)
Definitely no 10 (15)
Data analyst blinded  
Definitely yes 7 (10)
Probably yes 3 (5)
Probably no 37 (55)
Definitely no 20 (30)
Intention to treat  
Yes 38 (57)
Unclear 15 (22)
No 14 (21)
Free of selective reporting of  
outcomes  
Adequate 59 (88)
Not clear 5 (7)
Inadequate 3 (5)
Stopped early  
Total 7 (10)
For benefit 2 (3)
For harm 1 (2)
For insufficient accrual 4 (6)
Not reported 0 (0)
Follow up  
Mean percentage (range) 96% (57-100)